Popular
CAI · Health care · U.S.

Caris Life Sciences

Tests tumor samples to help doctors pick cancer treatments.

Company Health

66
/100
Healthy
A quick check of the business from its yearly reports (2023–2025). It doesn’t say whether the stock is a good buy.
Does it make money?
0 of 25 · Poor
It lost money last year: $8 of every $100 in sales.
Is it growing?
25 of 25 · Good
Sales grew about 63% a year over the last 2 years.
Can it handle what it owes?
25 of 25 · Good
It holds more cash than everything it owes.
Does it bring in spare cash?
16 of 25 · Okay
After paying for buildings and equipment, $8 of every $100 in sales was left as spare cash.

Who owns it

2 of 23 own it · Nobody changed their stake
bought lately
owns it
doesn’t own it
Didn’t report owning it: Whale Rock, Appaloosa, Melqart, D1 Capital, Light Street, Lone Pine, Third Point, TCI, Pershing Square, Himalaya Capital, Greenlight, Giverny Capital, Fundsmith, Semper Augustus, Akre
Their letters don’t mention it: Arquitos, Laughing Water, Alluvial, Bireme, Kingdom Capital, Saga Partners
From each fund’s latest 13F report (Jun 30, 2026). Funds that don’t file one: from their own letters.

The numbers

From Caris Life Sciences’ yearly reports. Tap a year to see its figures.

Sales and profit

Sales grew from $306 million in 2023 to $812 million in 2025, and it lost money every year.
2025
Sales
$812 million
Loss
$68.1 million

Spare cash each year

It had cash to spare in 1 of the 3 years, including $66.9 million in 2025.
2025
Spare cash
$66.9 million
Spare cash is the cash its business brought in, minus what it spent on buildings and equipment.

What it owns and what it owes

At the end of 2025 it owned $1.13 billion, including $796 million in cash, and owed $548 million.

Key facts

From its yearly report for 2025.
Sales
$812 million
Loss
$68.1 million
Spare cash
$66.9 million
Cash in the bank
$796 million
Everything it owes
$548 million
Year ends
December
Money shown in
U.S. dollars
Latest yearly report
10-K, filed Mar 3, 2026
Figures from Caris Life Sciences’ yearly reports to the SEC (EDGAR), collected Oct 12, 2026.
Not investment advice. Holdings come from public SEC reports and the funds’ own letters, and can be up to 4½ months old. How this works
Privacy policy